Missense variants in the X-linked gene PRPS1 cause retinal degeneration in females by Fiorentino, A et al.
 1 
Missense variants in the X-linked gene PRPS1 cause retinal degeneration in females 
Alessia Fiorentino1, Kaoru Fujinami1-4, Gavin Arno1,2, Anthony G. Robson1,2, Nikolas 
Pontikos1,5, Monica Arasanz Armengol2, Vincent Plagnol5, Takaaki Hayashi6, Takeshi Iwata3,  
Matthew Parker7,8, Tom Fowler7, Augusto Rendon7,9,  Jessica C. Gardner1, Robert H. 
Henderson2,10, Michael E. Cheetham1, Andrew R. Webster1,2, Michel Michaelides1,2*, Alison 
J. Hardcastle1*, for the 100,000 Genomes Project, the Japan Eye Genetic Consortium and the 
UK Inherited Retinal Disease Consortium 
Affiliations 
1UCL Institute of Ophthalmology, London, United Kingdom 
2 Moorfields Eye Hospital, London, United Kingdom 
3 National Institute of Sensory Organs, National Hospital Organization, Tokyo Medical 
Center, Tokyo, Japan 
4 Keio University School of Medicine, Tokyo, Japan 
5 UCL Genetics Institute, London, United Kingdom 
6 Department of Ophthalmology, The Jikei University School of Medicine, Tokyo, Japan 
7 Genomics England, Queen Mary University of London, London, United Kingdom 
8 Sheffield Diagnostic Genetics Service, Sheffield Children's Hospital, Sheffield, United 
Kingdom 
9 Department of Haematology, University of Cambridge, Cambridge, United Kingdom 
10Great Ormond Street Hospital for Children, Great Ormond Street, London, United Kingdom 
*Correspondence 
Alison J. Hardcastle, PhD, UCL Institute of Ophthalmology, 11-43 Bath St, EC1V 9EL, 
London, United Kingdom; E-mail: a.hardcastle@ucl.ac.uk 
Michel Michaelides, MD(Res), FRCOphth, UCL Institute of Ophthalmology, 11-43 Bath St, 
EC1V 9EL, London, United Kingdom; E-mail: michel.michaelides@ucl.ac.uk 
 2 
Grant Sponsors 
Supported by grants from the National Institute for Health Research Biomedical Research 
Centre at Moorfields Eye Hospital National Health Service Foundation Trust and UCL 
Institute of Ophthalmology (UK), Fight For Sight (UK), Moorfields Eye Charity (UK), the 
Foundation Fighting Blindness (USA), and Retinitis Pigmentosa Fighting Blindness (UK). 
Michel Michaelides is supported by an FFB Career Development Award. Kaoru Fujinami 
and Gavin Arno are supported by The Great Britain Sasakawa Foundation, Butterfield 
Awards for UK-Japan collaboration in medical research and public health Practice (UK). 
Kaoru Fujinami is supported by a Foundation Fighting Blindness Career Development Award 
(USA); KAKENHI, Grant-in-Aid for Young Scientists (A) and KAKENHI, Fund for the 
Promotion of Joint International Research, Fostering Joint International Research, The 
Ministry of Education, Culture, Sports, Science and Technology (Japan); the Japan Agency 
for Medical Research and Development, the Ministry of Health, Labor and Welfare (Japan); 
The Specified Disease Research Program on Intractable Diseases, The Ministry of Health 
Labour and Welfare (Japan); and National Hospital Organization Network Research Fund 
(Japan). Takaaki Hayashi is supported by JSPS KAKENHI Grant Number 17K11434. This 
research was aided by access to the data and findings generated by the 100,000 Genomes 
Project. The 100,000 Genomes Project is managed by Genomics England Limited (a wholly 
owned company of the Department of Health). The 100,000 Genomes Project is funded by 
the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer 
Research UK and the Medical Research Council have also funded research infrastructure. 
 3 
Abstract 
Retinal dystrophies are a heterogeneous group of disorders of visual function leading to 
partial or complete blindness. We report the genetic basis of an unusual retinal dystrophy in 
five families with affected females and no affected males. Heterozygous missense variants 
were identified in the X-linked PRPS1 gene: c.47C>T, p.(Ser16Phe); c.586C>T, 
p.(Arg196Trp); c.641G>C, p.(Arg214Pro) and c.640C>T, p.(Arg214Trp). Missense variants 
in PRPS1 are usually associated with disease in male patients, including Arts Syndrome, 
Charcot-Marie-Tooth and non-syndromic sensorineural deafness. In our study families, 
affected females manifested a retinal dystrophy with inter-ocular asymmetry. Three unrelated 
females from these families had hearing loss leading to a diagnosis of Usher Syndrome. 
Other neurological manifestations were also observed in three individuals.  
Our data highlight the unexpected X-linked inheritance of retinal degeneration in females 
caused by variants in PRPS1, and suggest that tissue specific skewed X-inactivation or 
variable levels of PRS-I deficiency are the underlying mechanism(s). We speculate that the 
absence of affected males in the study families suggests that some variants may be male 
embryonic lethal when inherited in the hemizygous state. The unbiased nature of next 
generation sequencing enables all possible modes of inheritance to be considered for 
association of gene variants with novel phenotypic presentation.  
Key Words Retinal Dystrophy, PRPS1, PRS-I, Next generation sequencing 
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1. Introduction 
Inherited retinal dystrophies (IRD) are a heterogeneous group of visual function disorders 
that lead to partial or complete blindness, affecting approximately 1 in 2500-3000 
individuals, and represent the commonest cause of blindness in the working age population 
and second commonest in childhood in England and Wales (Holt, et al., 2015; Liew, et al., 
2014). IRD may be classified according to whether there is a primary defect of cone or rod 
systems or both, and according to whether retinal dysfunction is generalised or confined to 
the central retina (macular dystrophy). These disorders can occur in isolation (non-syndromic 
IRD) or with additional systemic manifestations (syndromic IRD).  The genetic aetiology of 
IRD is remarkably heterogeneous, with over 300 disease-causing genes identified (The 
Retinal Information Network http://www.sph.uth.tmc.edu/RetNet/; accessed April 1st, 2017). 
The implicated genes are involved in the function of numerous pathways in the retina, 
including phototransduction, retinal metabolism, ciliogenesis and RNA splicing(Nash, et al., 
2015); however, the genetic cause of IRD in approximately 40% of cases remains unsolved 
(Ellingford, et al., 2016; Khan, et al., 2017).  
The identification of disease-causing variants in IRD has been accelerated by the 
implementation of next generation sequencing (NGS) technologies. Targeted NGS 
sequencing of known genes can identify disease-causing variants in an estimated 60% of non-
syndromic cases and 80% of syndromic cases (Bravo-Gil, et al., 2016; Ellingford, et al., 
2016; Glockle, et al., 2014). In patients that lack a molecular diagnosis, whole exome 
sequencing (WES) and whole genome sequencing (WGS) are effective tools to identify new 
potential causative genes and variants (Arno, et al., 2016; Audo, et al., 2014; Chaki, et al., 
2012) .  
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In our collaborative study of unsolved IRD cases, through the UK Inherited Retinal Disease 
Consortium, the Japan Eye Genetic Consortium and the 100,000 Genomes Project, 
approximately 1,614 unrelated individuals were analysed by WES or WGS. 
Here we describe retinal dystrophy in 9 affected females from 5 unrelated families with no 
affected males. Whole exome or whole genome sequencing (WES; WGS) revealed 
heterozygous missense variants in the Phosphoribosyl Pyrophosphate Synthetase 1 (PRPS1) 
gene, which are more usually implicated in rare syndromic disease in male patients including 
Arts Syndrome (MIM# 301835), X-linked Charcot-Marie-Tooth (CMTX5, MIM# 311070) 
and X-linked non-syndromic sensorineural deafness (DFNX1, MIM# 304500).    
2. Material and methods 
2.1 Clinical assessment of study families 
The study protocols adhered to the tenets of the Declaration of Helsinki and received 
approval from the local Ethics Committee of all participant institutes; Moorfields Eye 
Hospital, National Institute of Sensory Organs, and the Jikei University School of Medicine. 
Written, informed consent was obtained from all participants or parents of children prior to 
their inclusion in this study. Families 1 to 4 were recruited in the UK (Figure 1).  
Four probands, the affected mother of the proband of family 1, and the affected daughter of 
the proband of family 2 underwent detailed clinical examination, including best-corrected 
decimal visual acuity (BCVA), 35-degree color fundus photography (TRC-NW8, Topcon 
(Great Britain) Ltd., UK), ultra-widefield confocal scanning laser imaging (California, Optos 
plc, UK), fundus autofluorescence (FAF) imaging (Spectralis, Heidelberg Engineering Inc., 
CA), spectral-domain optical coherence tomography (SD-OCT; Spectralis, Heidelberg 
Engineering Inc., CA), kinetic and static visual field testing (Goldmann perimetry and 
Humphrey Field Analyzer, HFA3, Carl Zeiss Meditec AG, Germany), and color vision 
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testing with both Ishihara and Hardy Rand and Rittler Pseudoisochromatic plate testing. 
Family 5 was recruited in Japan. The proband and the two affected older daughters 
underwent clinical evaluation including measurements of the BCVA, visual field testing, 35-
degree color fundus photography (VISUCAM NM/FA; Carl Zeiss Meditec AG, Dublin, CA, 
USA), Spectralis HRA (Heidelberg Engineering, Heidelberg, Germany) for fundus 
autofluorescence imaging (5-III:2), and SD-OCT (Cirrus, Carl Zeiss Meditec AG, Germany), 
static visual field testing (Humphrey Field Analyzer, HFA3, Carl Zeiss Meditec AG, 
Germany), and color vision testing with Farnsworth D-15 test. 
 Full-field ERG assessment of generalised retinal function (Families 2, 4 and 5) and pattern 
ERG assessment of macular function (families 2 and 4) were performed with corneal 
electrodes and incorporated the standards of the International Society for Clinical 
Electrophysiology of Vision (Bach, et al., 2013; McCulloch, et al., 2015), with the exception 
of the flash ERGs in one child (2-IV:5), recorded using lower eyelid skin electrodes 
according to a paediatric protocol. 
2.2 Next Generation Sequencing 
DNA samples for the five probands were analysed by NGS: family 1, 2, 3 and 5 were 
investigated using WES and family 4 using WGS. For more details see Supp. material and 
methods. 
2.3 Sanger sequencing  
In order to confirm the PRPS1variants identified by NGS (position according to reference 
transcript NM_002764 and X-chromosome co-ordinates in hg19), polymerase chain reaction 
(PCR) amplification and bi-directional Sanger sequencing was performed using standard 
reagents and conditions, and oligonucleotide primers flanking the variant (primer sequences 
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available on request). Segregation analysis was performed where familial samples were 
available. 
2.4 In silico analysis of PRPS1 variants 
The UCSC genome browser (http://genome.ucsc.edu/) and Phenopolis 
(https://Phenopolis.github.io; (Pontikos, et al., 2016)) were used for visualisation and analysis 
of existing variation. Genetic variant deleteriousness was scored with PolyPhen v2.2.2 
(http://genetics.bwh.harvard.edu/pph2/; accessed on 11/01/2017; (Adzhubei, et al., 2010)) 
and SIFT (http://sift.jcvi.org/; accessed on 11/01/2017;  (Ng and Henikoff, 2001)). The 
evolutionary conservation of variants was assessed by multiple sequence alignment across 
species using Homologene (https://www.ncbi.nlm.nih.gov/homologene; accessed on 
11/01/2017). The impact of pathogenic variants on the three-dimensional structure of the 
protein was assessed with a model of phosphoribosyl pyrophosphate synthetase-1 (PRS-I) 
based on the crystal structure of the human PRS-I protein (Protein Database, PDB: 2H06, 
http://www.rcsb.org/pdb/home/home.do) using Swiss Model (Arnold, et al., 2006), 
https://swissmodel.expasy.org/, accessed on the April 1st, 2017) with standard parameters 
and visualizing it with YASARA v16.9.23 (http://www.yasara.org/; (Krieger and Vriend, 
2014)). PRPS1 variants associated with disease have been submitted to ClinVar 
(https://www.ncbi.nlm.nih.gov/clinvar/). 
3. Results 
3.1 Phenotypic Characteristics  
The phenotypic characteristics of nine affected individuals in the study families (Figure 1) are 
summarised in Table 1. The mean age in 2017 was 38 years with a range of 13 to 94 years. 
Photoaversion was reported in 3 patients (1-II:1, 3-II:1, 5-II:2) and 4 subjects had night 
blindness (2-IV:5, 5-II:2, 5-III:1, 5-III:2). Visual acuity reduction was described in 3 patients 
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(2-III:4, 4-II:1, 5-II:2), with one subject having blurred vision in the left eye due to 
intraocular lens dislocation (1-I:2). 
Visual acuity varied; two patients had severe visual loss (less than 6/36 in the better eye), and 
six had relatively preserved BCVA (better than 6/9 in the better eye). The mean age of onset 
of visual symptoms was 19 years with a range of 5 to 29 years.  
Fundus examination, color fundus photography, and FAF imaging identified a variable 
degree of patchy mid-peripheral retinal atrophy and/or retinal pigment epithelial disturbance 
in all patients, with a variable degree of inter-ocular asymmetry in all nine patients (Figures 
2-3). Retinal pigment epithelial (RPE) mottling and/or a tapetal-like reflex on FAF was 
observed in 6 out of 8 subjects with available images (1-II:1, 2-III:4, 2-IV:5, 3-II:1; 4-II:1, 5-
III:1; Figures 2-3). Macular involvement was apparent in four patients and optic disc atrophy 
was detected in seven (Table 1).  
SDOCT demonstrated outer retinal disruption in the atrophic regions of seven patients with 
available images (Figure 2, 1-II:1, 1-I:2, 2-III:4, 4-II:1, 5-II:2, 5-III:1, 5-III:2). Foveal 
structure was relatively preserved in five patients (1-II:1, 1-I:2, 4-II:1, 5-III:1, 5-III:2) and 
choroidal thickness was maintained in all seven subjects.  
Electrophysiological assessment was performed in five patients and showed generalized 
retinal dysfunction with a similar degree of cone and rod photoreceptor involvement in two 
subjects (2- III:4, 4-II:1), with mild worsening of rod system function in 4-II:1 between the 
ages of 6 and 12 years (Figure S1). In a 12-year-old girl there was ERG evidence of a cone-
rod dystrophy (2-IV:5) and in one other subject a cone dystrophy (5-III:1). The ERGs were 
normal in one patient (5-III:2). There was significant inter-ocular ERG asymmetry in cases 2-
III:4 (Figure S1) and 2-IV:5. Subjects that underwent additional PERG testing showed P50 
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reduction in keeping with severe macular involvement with evidence of progression in 4-II:1 
(Figure S1).  
Visual field testing was performed in six patients. Visual field defects corresponding to the 
amount of RPE atrophy was detected in these six patients, with a variable degree of 
interocular asymmetry. Constricted peripheral visual fields with relatively preserved central 
field were found in four patients (1-II:1, 4-II:1, 5-III:1, 5-III:2), and large central field defects 
with areas of residual peripheral field were observed in two subjects (2-III:4, 5-II:2). 
Generalised dyschromatopsia was detected in all four patients with available data (1-II:1, 2-
III:4, 2-IV:5, 5-II:2). 
Sensorineural hearing loss was reported in three patients (Table 1). Hearing loss was first 
reported in childhood and diagnosed in two patients (3-II:1, 4-II:1) and one subject showed 
severely reduced responses at the pure tone test in her 40s (5-II:2).  Asymmetrical hearing 
loss was reported in one patient (4-II:1), while there were multiple infection histories in the 
middle ear. 
Additional neurological abnormality was reported in three patients (1-II:1, 5-II:2, 5-III:2). 
Gait deficit was detected in one proband of family 1 (1-II:1), who was previously diagnosed 
with possible post-polio syndrome. The mother of this proband of family 1 (1-I:2) also had 
gait difficulty; however, detailed information is unavailable. Ataxia of gait was also detected 
in the proband and older daughter of the proband of family 5 (5-II:2, 5-III:1), while no ataxia 
was reported by the younger daughter of the proband (5-III:2). 
3.2 Identification of rare PRPS1 variants in affected females  
The pedigrees of the study families are shown in Figure 1. A female in Family 1 (GC20175, 
individual 1-II:1), was diagnosed with rod-cone dystrophy with inter-ocular asymmetry, 
inherited from her mother. Given the asymmetry of retinal degeneration and RPE mottling/ 
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tapetal-like retinal reflex in this individual, an X-linked condition was considered, which led 
to screening of Retinitis Pigmentosa 2 gene (RP2) and Retinitis Pigmentosa GTPase 
Regulator gene (RPGR) (including the Open Riding Frame 15 (ORF15)). As no pathogenic 
variant was identified, WES was performed and variants were filtered and prioritised for 
potential autosomal dominant or X-linked inheritance. Heterozygous rare variants with a 
maximum of 2 in 8000 alleles in University College London Exome (UCLEx N=4,000) and a 
maximum of 5 in 121412 alleles in the Exome Aggregation Consortium (ExAC, including 
WES data of 60,706 unrelated individuals without paediatric onset severe Mendelian disease) 
databases were identified in 88 autosomal genes and 3 genes on the X-chromosome (Supp. 
Table S1). A single heterozygous variant (GRCh37 Chr6:65301316, NM_001142800: 
c.4444G>A p.E1482K) was identified in Eyes Shut Homolog (EYS), a gene previously 
implicated in autosomal recessive Retinitis Pigmentosa (RP). In the absence of a second 
allele, this was deemed unlikely to be causative of the phenotype. Interestingly, a rare 
heterozygous missense variant was identified in the X-linked gene PRPS1 (Supp. Table S1, 
GRCh37 ChrX:106871905, NM_002764: c.47C>T (p.(Ser16Phe), RNA not analysed)) which 
was absent from the ExAC and Genome Aggregation Database (gnomAD) datasets and was 
predicted to be probably pathogenic by in silico prediction algorithms (Table 2).  
Variants in PRPS1 encoding the protein PRS-I cause rare forms of DFNX1, CMTX5, Arts 
Syndrome and PRS-I superactivity (MIM# 300661) in affected males (Gandia, et al., 2015; 
Mittal, et al., 2015). However, recently a family with only affected females with optic 
atrophy, RP and neurological features overlapping CMTX5 and Arts syndrome was reported 
with a PRPS1 variant affecting the same codon as we report in Family 1, c.46T>C, 
p.(Ser16Pro) (Almoguera, et al., 2014),  implicating the PRPS1 variant as the top candidate in 
Family 1. Sanger sequencing confirmed the PRPS1 variant in the affected female proband, 
and its absence in unaffected siblings (1-II:3 and 1-II:5, Figure 1 and Supp. Figure S2).  
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A simplex affected female (GC19753, individual 2-III:4) was diagnosed with an 
asymmetrical photoreceptor dystrophy with severe macular involvement. Given the inter-
ocular asymmetry of retinal degeneration in this individual, an X-linked condition was 
considered, and variants in RP2 and RPGR (including ORF15) were excluded. In addition, 
targeted capture sequencing of 176 genes (Manchester Centre for Genomic Medicine) known 
to be associated with IRD did not reveal a causative variant, so WES was performed. 
Variants were filtered and prioritised considering potential de novo, X-linked or recessive 
inheritance (see Supp. material and methods), revealing a PRPS1 variant as the most 
compelling candidate (GRCh37 ChrX:106888462; c.586C>T (p.(Arg196Trp), RNA not 
analysed); NM_002764). This variant was absent in the ExAC and gnomAD databases and 
was predicted to be potentially pathogenic by both Polyphen and SIFT (Table 2). Sanger 
sequencing confirmed the variant in the affected female proband. Subsequently, one of the 
proband’s daughters presented with vision problems (2-IV:5), and genotyping confirmed that 
she had inherited the PRPS1 variant c.586C>T, p.(Arg196Trp) (Supp. Figure S2).  
The proband (GC19557, 3-II:1) of family 3 was diagnosed with RP and hearing loss, initially 
described as atypical Usher syndrome type II or III, with no family history of the condition. 
Known genes associated with Usher syndrome (MYO7A, USH1C, CDH23, PCDH15, 
USH1G, USH2A, GPR98, WHRN, CLRN1, SLC4A7) were screened and were variant 
negative (National Collaborative Usher Study (Stabej, et al., 2012)). WES was performed and 
the variants were filtered and prioritised for all possible modes of inheritance (see Supp. 
material and methods).  A unique variant in PRPS1, (GRCh37 ChrX:106888516; c.640C>T 
(p.(Arg214Trp), RNA not analysed; NM_002764), was considered the most probable cause 
of disease. The variant was not found in the ExAC or gnomAD databases and was predicted 
to be potentially pathogenic by both Polyphen and SIFT (Table 2). Interestingly, the same 
variant was identified in the proband of family 4 (GC19559, 4-II:1) who was also diagnosed 
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with atypical Usher syndrome type II, with no family history. WGS was performed for the 
proband and her parents as part of the 100,000 genomes project (4-II:1, 4-I:1, 4-I:2) and 
variants were filtered and prioritised for potential de novo or autosomal recessive inheritance. 
No potential compound heterozygous or homozygous variants survived filtering (see Supp. 
material and methods).  A PRPS1 variant c.640C>T (p.(Arg214Trp), RNA not analysed) was 
considered the most compelling candidate, and was not found by WGS in the unaffected 
parents (4-I:1 and 4-II:2).  Sanger sequencing confirmed that the variant has occurred as a de 
novo variant in the affected female (Figure 1 and Supp. Figure S2). 
An affected female in Family 5 (5-II:2) was diagnosed with cone-rod dystrophy at the age of 
26. No family history was reported and there was a history of miscarriage before having three 
daughters. Fundus examination of her three daughters was normal (5-III:1, 5-III:2, 5-III:3) at 
that time. The latest clinical investigations were performed 16 years after the baseline 
diagnosis. The female proband had developed hearing loss and ataxia of gait was also noted. 
All three daughters reported visual impairment. Two had subtle fundus abnormalities with 
disc pallor (5-III:1, 5-III:2); and fundus abnormality, optic nerve hypoplasia and a gait deficit 
were detected in the youngest daughter (not included in this study). One, had ataxia of gait 
with evidence of cone dystrophy (5-III:2) and two individuals had inferior visual field defects 
(5-III:1, 5-III:2). WES was performed for the proband, and variants were filtered and 
prioritised for potential de novo, X-linked or recessive inheritance. A variant, c.641G>C 
(p.(Arg214Pro), RNA not analysed) (GRCh37 ChrX:106888517; NM_002764), in PRPS1 
was identified as the most likely cause. This variant was absent in the ExAC or gnomAD 
databases and was predicted to be possibly pathogenic by SIFT (Table 2). Sanger sequencing 
confirmed the variant in the proband and absence in her unaffected mother and sister (5-I:2 
and 5-II:3). Two symptomatic daughters available for genetic testing were found to carry the 
PRPS1 variant (5-III:1 and 5-III:2, Figure 1 and Supp. Figure S2).   
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3.3 Pathogenicity and potential consequences of missense variants in PRPS1 
All four rare PRPS1 missense variants (p.Ser16Phe, p.Arg196Trp, p.Arg214Pro and 
p.Arg214Trp) identified in this study are absent from control datasets and are predicted to be 
damaging by both SIFT and Polyphen, (with the exception of p.Arg214Pro, Table 2). Where 
samples were available, the variants segregated with the phenotype in families (Figure 1 and 
Supp. Figure S2). Multiple sequence alignment of PRS-I orthologues confirmed that the 
serine residue at position 16 and the arginine residues at positions 196 and 214 are highly 
conserved in orthologues at least to zebrafish (Figure 4A). PRS-I is highly conserved across 
different species, with 100% conservation in primates, wolf, cow, mouse and rat, and over 
88% conservation in insects. Variants in PRPS1 have been previously associated with 
different phenotypes in males: DFNX1, CMTX5, Arts Syndrome, PRS-I superactivity and 
some overlapping phenotypes. Causative variants for these different hemizygous phenotypes 
have been identified in coding exons 2 to 7. In PRPS1 exon 1, only one variant (p.Ser16Pro) 
has been identified in a single family with only affected females (Figure 4B).  The 
phenotypes associated with previously reported variants are summarised in Figure 4B. 
PRPS1 codes for the enzyme PRS-I, a 318 amino acid protein that catalyses the synthesis of 
phosphoribosyl pyrophosphate (PRPP) from adenosine triphosphate (ATP) and ribose-5-
phosphate (R5P) (Becker, 2001; Kornberg, et al., 1955). PRPP is essential for the de novo 
synthesis of purine (Hartman and Buchanan, 1958), pyrimidine (Lieberman, et al., 1955), and 
pyridine nucleotides (Preiss and Handler, 1958). PRS-I acts as a hexamer, which consists of 
three homodimers arranged in a propeller-like shape (Figure 5A) (de Brouwer, et al., 2010; 
Li, et al., 2007). Each of the homodimers has an active site, comprising the binding site for 
ATP (including the flexible loop, the PPi binding loop and the flag region) and R5P (Figure 
4B), and two regulatory allosteric sites, I and II (de Brouwer, et al., 2010; Li, et al., 2007).  
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Three-dimensional modelling of PRS-I indicates that serine 16 is located in the first α-helix 
of the protein in the N-terminal domain, while the two affected arginine residues at position 
196 and 214 are located in random coils (Figure 5 B, C, D). Serine 16 has been previously 
predicted to create a hydrogen bond with Glycine 13 using Swiss Model based on the PDB 
2H06 model (Almoguera, et al., 2014). In the crystallography model, the side chain of 
Arginine 196 is in close proximity to the bound ATP, with a distance between the 
guanidinium group of the Arginine and the α-phosphate of ATP of about 7.4 Å (Li, et al., 
2007). This close proximity suggests that Arginine 196 is involved in the interaction of PRS-I 
with the PPi, and in the stabilization of the transition state (Li, et al., 2007). The substitution 
of this conserved arginine with tryptophan has been previously predicted to abolish this 
interaction, resulting in decreased enzyme activity (Mittal, et al., 2015). This has been noted 
in the three-dimensional model created using Swiss Model (Arnold, et al., 2006) in which the 
substitution, Arg196Trp, alters the conformation of the connection loop between two β-sheets 
(Figure 5B). Arginine 214 forms part of the binding site of the R5P (Figure 4B) and in the 
three-dimensional model the substitution of arginine 214 with tryptophan leads to the loss of 
a hydrogen bond with cysteine 165, possibly altering the binding site for R5P (Figure 5C). 
The same hydrogen bond is lost with the substitution of arginine 214 to proline (Figure 5D). 
Therefore, all of the variants identified are predicted to either disrupt the function, or 
stability, of PRS-1. 
4. Discussion 
Here we characterise an inherited retinal dystrophy in five families in which only female 
members were affected, including cases with markedly asymmetrical disease on fundus 
examination, retinal imaging and/or functional phenotyping. Variable clinical presentation 
was evident in the nine affected subjects, consistent with previous reports (Al-Maawali, et al., 
2015; Almoguera, et al., 2014), including variable disease onset and visual acuity, fundus 
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appearance, and evidence of hearing loss and/or systemic abnormality. Almoguera and 
colleagues reported variable onset in six affected patients with PRPS1-associated disorders, 
including initial presentation of optic atrophy, night blindness and reduced visual acuity, 
followed by presentation of retinitis pigmentosa, and later onset of hearing impairment and 
neurological abnormalities.  In our 5 youngest cases (younger than 30 years at the latest 
examination), optic disc atrophy was observed in 4, one had night blindness and one had 
reduced visual acuity. Retinal atrophy was present at a wide range of ages in our cohort. 
The absence of macular involvement was common, with maintained foveal structure and 
function observed even in a patient at the age of 71 (1-II:1). Two patients with RPE 
disturbance at the macula maintained BCVA (2-IV:5, 3-II:1). However, one subject (4-II:1) 
had severely reduced macular function (as detected with pattern ERG; a 15-degree stimulus 
field), with maintained foveal structure and function (as was detected, and can be monitored 
over time, with multifocal ERG) (Almoguera, et al., 2014; Fujinami, et al., 2013). Full-field 
ERGs showed a similar degree of generalised cone and rod photoreceptor dysfunction or 
predominant or selective cone system dysfunction, and were normal in one young case (5-
III:2). Overall, these observations demonstrate the importance of comprehensive assessment 
of both generalised retinal and macular structure and function in the diagnosis and monitoring 
of PRPS1 retinopathy. 
Hearing impairment was reported in three patients (20 to 71 years at the latest examination) 
and systemic abnormalities were found in three (17 to 45 years). Our study also suggests 
earlier presentation of optic atrophy and later presentation of hearing impairment and 
systemic abnormalities; although there was still a degree of variability and further 
investigation with longitudinal analysis would be needed to confirm these observations. 
Overall, these findings illustrate that PRPS1-associated disorders can be progressive and 
affect multiple organs, such that careful observation with systemic survey is encouraged. 
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NGS analysis of families with only affected females revealed an X-linked mode of 
inheritance and causative variants in PRPS1, with four missense variants (c.47C>T, 
p.(Ser16Phe); c.586C>T, p.(Arg196Trp); c.640C>T, p.(Arg214Trp); c.641G>C, 
p.(Arg214Pro))  identified in five unrelated families. The common phenotype in all cases was 
patchy bilateral retinal degeneration, frequently asymmetrical with RPE mottling and/or a 
tapetal-like reflex in most FAF images and with evidence of cone or cone and rod 
dysfunction in most. It is noted that in the absence of a family history, similar asymmetrical 
features may be confused with some acquired or inflammatory retinal disorders. A high 
proportion of adult obligate carriers of X-linked RP manifest fundus abnormalities, such as a 
tapetal reflex and full-field ERG abnormalities which are frequently asymmetrical. This may 
be attributed to skewed inactivation of X-chromosomes in females, whereby a higher 
proportion of cells express the variant, rather than wild-type allele.  
In a previous report (Almoguera, et al., 2014), skewed X chromosome inactivation was 
experimentally tested in blood leukocytes from three patients, whose symptoms included 
IRD. Only one of the affected individuals showed significant asymmetric inactivation, that 
correlated with the severity of the phenotype. The lack of a skewed pattern of X-inactivation 
in two other subjects does not exclude this mechanism, as it may be tissue specific (Van den 
Veyver, 2001) and restricted to tissues primarily affected in this condition, i.e. the retina or 
the nervous system. 
Interestingly, three affected individuals from families 3, 4, and 5 also presented with hearing 
loss, caused by different missense variants affecting the same amino acid residue, 
p.Arg214Trp and p. Arg214Pro. These variants occurred de novo in families 4 (4-II:1) and 5 
(5-II:2) and are the only variants reported in this study that are associated with hearing 
impairment.  
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In our study, disease progression was confirmed in the three affected females in family 5. 
Hearing loss and ataxia developed in the proband in her forties and ocular manifestations of 
retinal changes and disc pallor were first confirmed in the two affected daughters in their 
twenties. A progressive phenotype has previously been reported for affected females 
diagnosed with CMTX5 (Almoguera, et al., 2014; Park, et al., 2013; Synofzik, et al., 2014).  
The majority of reported PRPS1 missense variants cause a reduction in PRS-I enzymatic 
activity (Almoguera, et al., 2014; Gandia, et al., 2015). There is considerable variation in the 
resulting phenotype in hemizygous males, including DFNX1, CMTX5 disease and Arts 
Syndrome, and the phenotypic severity is considered to be related to the degree of reduced 
PRS-I activity. Modest reductions in activity are associated with X-linked non-syndromic 
sensorineural deafness where patients have post-lingual progressive hearing loss. A moderate 
reduction of enzymatic activity is associated with X-linked CMTX5 where affected 
individuals develop hearing impairment, optic atrophy and peripheral neuropathy. More 
severe reductions of PRS-I activity are associated with Arts Syndrome, characterised by 
hearing impairment, optic atrophy, peripheral neuropathy, central neuropathy and a deficient 
immune response.  
Severe PRS-I deficiency associated with the p.Arg196Trp variant has been reported in two 
male siblings with central neuropathy, including severe developmental delay and spastic 
quadraparesis, in addition to prenatal growth retardation and dysmorphic facial features (Al-
Maawali, et al., 2015). Additional reported phenotypic features include macular coloboma-
like lesions with retinal dystrophy, short stature and diabetes insipidus. Here we report two 
additional affected females with this variant (family 2). 
PRS-I superactivity has also been implicated as the cause of disease resulting from missense 
variants, characterised by hyperuricemia and hyperuricosuria resulting in childhood gout. 
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Similar to the reduction in PRS-I enzymatic activity, PRS-I superactivity results in a wide 
range of phenotypes: patients with a milder phenotype have uric acid crystalluria or urinary 
stones as the first clinical sign, followed by gout arthritis if the uric acid level is not 
controlled. More severe phenotypes are characterized by early childhood gout arthritis that is 
also accompanied with a combination of neurodevelopment abnormalities, hypotonia, ataxia 
and sensorineural hearing loss (Mittal, et al., 2015). 
Although most female carriers in families with PRPS1 variants were noted to be 
asymptomatic (Kim, et al., 2007), some studies report that female carriers in families with 
Arts syndrome or CMTX5 occasionally exhibit delayed onset hearing impairment, sometimes 
combined with ataxia and neuropathy (Almoguera, et al., 2014; Arts, et al., 1993; de 
Brouwer, et al., 2010; Kim, et al., 2016; Liu, et al., 2010; Synofzik, et al., 2014). In addition, 
a missense variant, p.Ser16Pro, has been reported in affected females in one family as the 
cause of optic atrophy, RP and neurological features overlapping CMTX5 and Arts 
syndrome, with no affected males (Almoguera, et al., 2014). The same amino acid residue is 
substituted in Family 1 (p.Ser16Phe) with a similar phenotypic presentation. 
While it has not been possible to experimentally confirm the PRS-I activity in our patients, 
the missense variant, p.Arg196Trp, in family 2 has been shown to reduce PRS-I enzymatic 
activity (Al-Maawali, et al., 2015). A similar decrease of enzymatic activity in females was 
reported for the missense variant p.Ser16Pro (Almoguera, et al., 2014), a different 
substitution at the same amino acid position affected in Family 1 (p.Ser16Phe). It is likely 
that substitution at the same amino acid position will have a similar effect on PRS-I activity. 
The phenotype of families 3 (p.Arg214Trp), 4 (p.Arg214Trp) and 5 (p.Arg214Pro) is 
consistent a decrease of PRS-I enzymatic activity. 
5. Conclusions 
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Skewed X-inactivation and/or variable levels of PRS-I deficiency or hyperactivity most likely 
contribute to the phenotypic variability of disease in males and females with missense 
variants in PRPS1. We speculate that the absence of affected males in the study families, and 
rarity of the variants in the population, suggests that some of these variants may not be 
tolerated when inherited in the hemizygous state in males and could be male embryonic 
lethal. Indeed, of the three affected amino acid positions 16, 196 and 214 that give rise to a 
phenotype in females, only one has been previously reported in affected males with the most 
severe phenotype caused by a PRPS1 variant; of four male children, only two survived the 
pregnancy and one died during childhood (Al-Maawali, et al., 2015). The phenotype included 
severe intellectual disability and spastic quadraparesis, macular coloboma-like lesions with 
retinal dystrophy, short stature and diabetes insipidus. Alternatively selective involvement of 
females could be indicative of male sparing rather than male lethality (Ryan, et al., 1997).  
The high conservation of the protein sequence is reflected in the lack of nucleotide variability 
across human genomes. In the ExAC database, there are no loss of function variants and only 
8 missense variants were identified in the major isoform, whereas a gene of similar size to 
PRPS1 would be expected to harbour on average 6.4 loss-of-function and 76.4 missense 
variants. The discrepancy between observed and expected variant rate, leads to this gene 
having a high probability of loss-of-function intolerance (pLI= 0.87) (Lek, et al., 2016). If 
population variability is only considered for hemizygous variants, the number of variants 
drops even further with only one missense variant identified in PRPS1 in the general 
population.  
To date, only variants at amino acid position 16, 196 and 214 have been associated with a 
retinopathy. More patients need to be investigated both genetically and phenotypically before 
it will be possible to reach any conclusion on the specific role of these residues, or the 
relationship between specific domains of PRS-I and retinal function. 
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Patients with Arts syndrome have shown an encouraging response to a trial intervention with 
S-adenosylmethionine (SAM), as a substrate for the alternative purine synthesis pathway (de 
Brouwer, et al., 2010; Liu, et al., 2013). SAM can replenish ATP and GTP independently of 
PRPP by direct conversion into adenine via the polyamine pathway. In addition, 
methyltransferases convert SAM into S-adenosylhomocysteine, which can be transformed 
into adenosine and adenine by S-adenosylhomocysteine hydrolase (de Brouwer, et al., 2010). 
Treatment with SAM could therefore be considered for patients with PRPS1 retinopathy to 
potentially slow the progression of retinal degeneration.  
This report highlights the unexpected finding of retinal degeneration in females caused by 
missense variants in the X-linked gene PRPS1 and expands our understanding of the 
phenotypic outcome of specific variants. The features of retinal degeneration include RPE 
mottling described as a tapetal-like reflex and intraocular asymmetry, and are similar to those 
seen in some female carriers of RPGR and RP2 (Ebenezer, et al., 2005; Kousal, et al., 2014; 
Pelletier, et al., 2007; Tee, et al., 2016), and PRPS1 should be considered in females with 
such generalised retinal dystrophy after exclusion of the more common causes, especially in 
the absence of affected males in an extended family. 
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Figure Legends 
Figure 1. Retinal dystrophy pedigree structure and segregation of PRPS1 variants 
Pedigrees of five study families (families 1 to 5) with affected females and no affected males. 
An arrow indicates the proband in each family. The PRPS1 variant identified in each family 
is indicated (position according to reference transcript NM_002764). Mut = PRPS1 causative 
variant present, WT = wild type allele, ? indicates that the disease status of the individual is 
unknown.  
 
Figure 2.  Retinal imaging of an affected individual (1-II:1) of Family 1 with PRPS1 
pathogenic variant (c.47C>T p.(Ser16Phe)) and two affected individuals of Family 2 (2-
III:4; 2-IV:5) with PRPS1 pathogenic variant (c.586C>T, p.(Arg196Trp)) 
A fundus photograph of Subject 1-II:1 diagnosed with rod-cone dystrophy and possible 
neurological abnormality shows localized multiple atrophic regions with retinal pigment 
epithelial (RPE) disturbance, intraretinal bone spicule pigmentary deposition, attenuated 
retinal vessels, and pale disc in the right eye (A). Fundus autofluorescence (FAF) imaging 
identified multiple areas of reduced autofluorescence corresponding to areas of atrophy seen 
clinically and additional areas of increased signal with marked inter-ocular asymmetry (B. 
right eye; C. left eye).  Spectral domain optical coherence tomography (SDOCT) 
demonstrated relative preservation of foveal lamination with loss of peripheral macular outer 
retinal structure (D). Fundus photographs of Subject 2-III:4 diagnosed with non-syndromic 
cone-rod dystrophy show asymmetrical diffuse RPE atrophic changes at the posterior pole 
with macular involvement (E. right eye; F. left eye). FAF imaging identified multiple areas of 
low signal surrounded by areas of high signal, corresponding to the retinal changes, with 
marked inter-ocular asymmetry (G. right eye; H. left eye). Fundus photographs of Subject 2-
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IV:5 diagnosed with non-syndromic cone-rod dystrophy show asymmetrical mild disturbance 
of the RPE at the posterior pole with macular involvement, and mottled RPE and/or tapetal-
like reflex. (I. right eye; J. left eye). FAF imaging identified areas of high signal at the 
posterior pole, corresponding to the retinal disturbance (K. right eye; L. left eye).  
 
Figure 3.  Retinal imaging of an affected individual of Families 3 with PRPS1 
pathogenic variant (c.640C>T, p.(Arg214Trp)) and two affected individuals of Family 5 
with PRPS1 pathogenic variant (c.641G>C, p.(Arg214Pro)) 
Fundus photographs of Subject 4-II:1 diagnosed with atypical Usher syndrome type II shows 
mild diffuse RPE disturbance temporally and pale optic discs, with mottled RPE and/or 
tapetal-like reflex (A. right eye; B. left eye). FAF imaging identified multiple areas of high 
signal, corresponding to the retinal changes (C. right eye; D. left eye). Fundus photographs of 
Subject 5-II:2 diagnosed with cone-rod dystrophy, hearing loss, and ataxia revealed severe 
atrophic changes mainly at the posterior pole (E. right eye; F. left eye). FAF imaging of 
Subject 5-III:2 diagnosed with cone-rod dystrophy and ataxia identified multiple areas of 
high signal, with inter-ocular asymmetry (G. right eye; H. left eye).  
Figure 4. Schematic of PRPS1 gene and PRS-I protein structure 
(A) Multiple sequence alignment orthologues shows that the serine 16, arginine 196 and 
arginine 214 are highly conserved across different species. (B) Schematic of the genomic and 
protein structure. Representation of the positions of PRS-I missense variants identified in this 
study (in black below the gene structure), and previously known missense variants causing 
Deafness X-linked 1 (in purple), PRS-I superactivity (in green), Arts syndrome (in orange), 
Charcot-Marie-Tooth disease 5 (in blue). The variants previously associated with a retina 
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dystrophy phenotype are represented in red (only in females) and brown (syndromic male 
phenotype). Position according to reference transcript NM_002764. 
Figure 5. Predicted effect of missense variants on the 3D PRS-I Protein Structure   
(A) Model of PRS-I hexamer based on the crystal structure (PDB: 2H06). Highlighted in 
blue, light blue and red respectively are the domains containing amino acid position 16, 196 
and 214. (B) Close-up model of amino acid position 196 with yellow/red as wild type and 
blue/light blue representing the p.Arg196Trp mutant. The substitution alters the conformation 
of the connection loop between two β-sheets as pointed out by the arrows. (C) Close-up 
structure model of the amino acid position 214. In yellow/red the wild type and in red/ blue 
the p.Arg214Trp variant. Arrows show the loss of a hydrogen bond between amino acids 214 
and cysteine 165 due to the p.Arg214Trp substitution. (D) Close-up structure model of the 
amino acid position 196. In yellow/red the wild type and in blue/light blue the p.Arg214Pro 
variant. Arrows show the loss of a hydrogen bond between amino acids 214 and cysteine 165 
due to the p.Arg214Pro substitution. 
  
